Alpha Cognition vs Lineage Cell Therapeutics
ACOG and LCTX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ACOG and LCTX compare
Lineage Cell Therapeutics is the larger company, worth 1.3 times as much as Alpha Cognition ($231M against $181M).
Lineage Cell Therapeutics keeps more of each dollar of sales as profit, with a net margin of 16.2% compared with −145% at Alpha Cognition.
Lineage Cell Therapeutics scores higher on the StockData Score (8 against 6 for Alpha Cognition), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ACOG | LCTX |
|---|---|---|
| Size and price | ||
| Market cap | $181M | $231M |
| Share price | $8.30 | $0.915 |
| Change, 1 year | 35.6% | −52.6% |
| Change, 5 years | −63.3% | −60.1% |
| Beta (5Y) | 0.34 | 0.96 |
| Employees | 72 | 77 |
| StockData Score | ||
| Total score | 6 | 8 (better) |
| Valuation score | 0 | 0 |
| Growth score | 0 | 0 |
| Performance score | 0 | 3 (better) |
| Health score | 6 (better) | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 8.9× (better) | 21.3× |
| P/B | 3.7× | 3.4× (better) |
| FCF yield | −17.1% | −11.4% (better) |
| Fair value | $5.01 | $0.620 |
| Margin of safety | −65.7% | −47.6% (better) |
| Growth | ||
| Revenue growth (TTM) | – | 0.18% |
| Revenue growth, 5Y average | – | 51.5% |
| Profitability | ||
| Gross margin | 92.9% | – |
| Operating margin | −147% (better) | −280% |
| Net margin | −145% | 16.2% (better) |
| FCF margin | −153% (better) | −244% |
| Return on equity | −72.9% | 3.9% (better) |
| Return on invested capital | −684% (better) | −1395% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 7.13 (better) | 5.96 |
| Altman Z-score | 4.50 (better) | −2.87 |
| Piotroski F-score | 3 | 4 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 48.7% | 46.1% |
| Held by insiders | 5.3% | 74.4% |
| Insider net buying, 12 months | $8.3M (better) | $24.4K |
| Short interest, % of float | 2.0% | 37.7% |
Go deeper
- ACOG stock overview
- ACOG income statement
- ACOG valuation and score
- LCTX stock overview
- LCTX income statement
- LCTX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.